AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 377153 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (Flagyl)
Number of subjects: 100
Study 377153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 30706535 — intervention group
Group type: EXPERIMENTAL
Intervention: Three Dimensions for Diabetes (3DFD) intervention
Number of subjects: 0
Study 30706535 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study 31562151 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational inequalities in self-rated health (SRH)
Number of subjects: 54197
Study 31562151 — intervention group
Group type: EXPERIMENTAL
Intervention: Income inequalities in self-rated health (SRH)
Number of subjects: 54197
Study 31562151 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative indices of inequality (RII) by education
Number of subjects: 54197
Study 31562151 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative indices of inequality (RII) by income
Number of subjects: 54197
Study 29172680 — intervention group
Group type: EXPERIMENTAL
Intervention: DR/ER-MPH (40-80 mg/day)
Number of subjects: 161
Study 24997071 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Assessment Response (FAR)
Number of subjects: 0
Study 24997071 — intervention group
Group type: COMPARATOR
Intervention: Investigation Response (IR)
Number of subjects: 0
Study 24798277 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifalazil (25 mg)
Number of subjects: 82
Study 24798277 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin (1 g)
Number of subjects: 82
Study 21946903 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors using hot flash treatments
Number of subjects: 237
Study 21946903 — intervention group
Group type: COMPARATOR
Intervention: Midlife women using hot flash treatments
Number of subjects: 237
Study 21946903 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 237
Study 21946903 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors
Number of subjects: 237
Study 21946903 — intervention group
Group type: COMPARATOR
Intervention: Midlife women
Number of subjects: 237
Study 19651710 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 103
Study 19651710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 19651710 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (among subjects with prestudy alcohol use)
Number of subjects: 103
Study 19651710 — intervention group
Group type: COMPARATOR
Intervention: Placebo (among subjects with prestudy alcohol use)
Number of subjects: 103
Study 17599440 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SESs)
Number of subjects: 75
Study 17599440 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMSs)
Number of subjects: 75
Study 17599440 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlapping SESs
Number of subjects: 75
Study 17599440 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoverlapping SES segments
Number of subjects: 75
Study 15162364 — intervention group
Group type: EXPERIMENTAL
Intervention: Kava extract WS 1490 (150 mg per day)
Number of subjects: 50
Study 15162364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 12240460 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge translation interventions
Number of subjects: 0
Study 12240460 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic reviews of the literature
Number of subjects: 0
Study 10194235 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir implant plus oral ganciclovir (4.5 g daily)
Number of subjects: 377
Study 10194235 — intervention group
Group type: COMPARATOR
Intervention: Ganciclovir implant plus oral placebo
Number of subjects: 377
Study 10194235 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ganciclovir alone
Number of subjects: 377
Study 10194235 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir or intravenous ganciclovir
Number of subjects: 377
Study 7582042 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic treatment studies
Number of subjects: 0
Study 7582042 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions for noncognitive or behavioral symptoms
Number of subjects: 0
Study 7582042 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical approaches to slow disease progression
Number of subjects: 0
Study 2253196 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rhIL-2 (1 x 10(6) units/m2 i.v. over 6 h on days 1-5 and 8-12) and R24 (1 mg/m2 daily)
Number of subjects: 20
Study 2253196 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rhIL-2 (1 x 10(6) units/m2 i.v. over 6 h on days 1-5 and 8-12) and R24 (3 mg/m2 daily)
Number of subjects: 20
Study 2253196 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rhIL-2 (1 x 10(6) units/m2 i.v. over 6 h on days 1-5 and 8-12) and R24 (8 mg/m2 daily)
Number of subjects: 20
Study 2253196 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rhIL-2 (1 x 10(6) units/m2 i.v. over 6 h on days 1-5 and 8-12) and R24 (12 mg/m2 daily)
Number of subjects: 20
Study 2253196 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rhIL-2 and R24
Number of subjects: 20
Study 7114512 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicergoline (0.3 mg/kg bolus, 0.8 mg/kg/h maintenance)
Number of subjects: 43
Study 31619358 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-Incision Lenticule Extraction (SMILE)
Number of subjects: 70
Study 31619358 — intervention group
Group type: COMPARATOR
Intervention: LASIK
Number of subjects: 70
Study 30933867 — intervention group
Group type: EXPERIMENTAL
Intervention: Snoezelen multisensory environment treatment
Number of subjects: 40
Study 30933867 — intervention group
Group type: COMPARATOR
Intervention: Control group (without treatment)
Number of subjects: 40
Study 27768397 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (Cr) supplementation (0.3 g・kg‐1・d‐1 for 5 days followed by 0.1 g・kg‐1・d‐1 for 23 days; n = 9)
Number of subjects: 17
Study 27768397 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA; n = 8)
Number of subjects: 17
Study 26375599 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue-mediated photodynamic inactivation followed by low-laser therapy
Number of subjects: 40
Study 26375599 — intervention group
Group type: COMPARATOR
Intervention: Miconazole gel
Number of subjects: 40
Study 25086636 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 127
Study 25086636 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 127
Study 25086636 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab or Lapatinib
Number of subjects: 127
Study 23038944 — intervention group
Group type: EXPERIMENTAL
Intervention: PAPM intervention group
Number of subjects: 254
Study 23038944 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional instruction intervention group
Number of subjects: 254
Study 23038944 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 254
Study 19944914 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally and linguistically adapted physical activity intervention (Seamos Activas)
Number of subjects: 93
Study 19944914 — intervention group
Group type: COMPARATOR
Intervention: Wellness contact control condition
Number of subjects: 93
Study 17244786 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg
Number of subjects: 16
Study 17244786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15346841 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration (Group 2)
Number of subjects: 131
Study 15346841 — intervention group
Group type: COMPARATOR
Intervention: No thrombus aspiration (Group 1)
Number of subjects: 131
Study 11602217 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger induced by harassment
Number of subjects: 0
Study 11602217 — intervention group
Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 0
Study 11602217 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunity to express anger
Number of subjects: 0
Study 11602217 — intervention group
Group type: COMPARATOR
Intervention: No opportunity to express anger
Number of subjects: 0
Study 11706524 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (FLU) administered for 2 weeks before LH-RHa
Number of subjects: 24
Study 11706524 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment (Control group)
Number of subjects: 24
Study 9150581 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants induced to feel sad
Number of subjects: 0
Study 9150581 — intervention group
Group type: COMPARATOR
Intervention: Participants not induced to feel sad
Number of subjects: 0
Study 7970483 — intervention group
Group type: COMPARATOR
Intervention: Conjugated estrogens (0.625 mg/day) alone
Number of subjects: 525
Study 7970483 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (0.625 mg/day) + MPA (2.5 mg/day continuously)
Number of subjects: 525
Study 7970483 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (0.625 mg/day) + MPA (5.0 mg/day continuously)
Number of subjects: 525
Study 7970483 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (0.625 mg/day) + MPA (5.0 mg/day for last 14 days of each cycle)
Number of subjects: 525
Study 7970483 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (0.625 mg/day) + MPA (10.0 mg/day for last 14 days of each cycle)
Number of subjects: 525
Study 3591644 — intervention group
Group type: EXPERIMENTAL
Intervention: LIGHT
Number of subjects: 9
Study 3591644 — intervention group
Group type: EXPERIMENTAL
Intervention: SCBA
Number of subjects: 9
Study 3591644 — intervention group
Group type: EXPERIMENTAL
Intervention: FF
Number of subjects: 9
Study 3591644 — intervention group
Group type: EXPERIMENTAL
Intervention: CHEM
Number of subjects: 9
Study 1960555 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin followed by CMF
Number of subjects: 0
Study 1960555 — intervention group
Group type: COMPARATOR
Intervention: CMF/Adriamycin
Number of subjects: 0
Study 1105487 — intervention group
Group type: EXPERIMENTAL
Intervention: prazosin alone
Number of subjects: 24
Study 1105487 — intervention group
Group type: EXPERIMENTAL
Intervention: prazosin plus one or more other antihypertensive drugs
Number of subjects: 24
Study 28768617 — intervention group
Group type: EXPERIMENTAL
Intervention: Physically enhanced environment
Number of subjects: 103
Study 28768617 — intervention group
Group type: COMPARATOR
Intervention: Standard environment
Number of subjects: 103
Study 28768617 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group
Number of subjects: 103
Study 27746370 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin 8% patch
Number of subjects: 369
Study 27746370 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 369
Study 27667379 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 18000
Study 27667379 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18000
Study 24880778 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic thrust manipulation
Number of subjects: 52
Study 24880778 — intervention group
Group type: COMPARATOR
Intervention: Thoracic non-thrust mobilization
Number of subjects: 52
Study 21822907 — intervention group
Group type: EXPERIMENTAL
Intervention: OTRa (Atosiban tractocide) 7.5 mg intravenous, administered 2 days after embryo transfer.
Number of subjects: 26
Study 21822907 — intervention group
Group type: COMPARATOR
Intervention: Control group (no OTRa administration).
Number of subjects: 26
Study 19875041 — intervention group
Group type: EXPERIMENTAL
Intervention: Summative index (SI) of guideline adherence for acute pain management
Number of subjects: 0
Study 17635851 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (80 mg/d) administered at bedtime
Number of subjects: 215
Study 17635851 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan (80 mg/d) administered on awakening
Number of subjects: 215
Study 14693607 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib oral suspension 25 mg (Group B)
Number of subjects: 48
Study 14693607 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib oral suspension 50 mg (Group C)
Number of subjects: 48
Study 14693607 — intervention group
Group type: COMPARATOR
Intervention: Placebo oral suspension (Group A)
Number of subjects: 48
Study 12491077 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy (JCOG 8801 study)
Number of subjects: 555
Study 9832295 — intervention group
Group type: COMPARATOR
Intervention: Compression treatment
Number of subjects: 0
Study 9832295 — intervention group
Group type: EXPERIMENTAL
Intervention: Horse chestnut seed extract (HCSE)
Number of subjects: 0
Study 9832295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8581790 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss interventions (specifics not provided)
Number of subjects: 0
Study 8581790 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 2223157 — intervention group
Group type: EXPERIMENTAL
Intervention: Bestatin treatment in squamous cell carcinoma
Number of subjects: 153
Study 2223157 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bestatin) in squamous cell carcinoma
Number of subjects: 153
Study 2223157 — intervention group
Group type: EXPERIMENTAL
Intervention: Bestatin treatment in adenocarcinoma
Number of subjects: 153
Study 2223157 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bestatin) in adenocarcinoma
Number of subjects: 153
Study 349961 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteinase inhibiting agents and glucagon
Number of subjects: 103
Study 349961 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy only
Number of subjects: 103
Study 30347523 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuebingen's Sectio Chirurgica (TSC) video
Number of subjects: 114
Study 30347523 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture video
Number of subjects: 114
Study 28463522 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (30% CM first bolus, 70% CM second bolus)
Number of subjects: 192
Study 28463522 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (70% CM first bolus, 30% CM second bolus)
Number of subjects: 192
Study 28463522 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (50% CM first bolus, 50% CM second bolus)
Number of subjects: 192
Study 28463522 — intervention group
Group type: COMPARATOR
Intervention: All groups (A, B, C) with different imaging delays
Number of subjects: 192
Study 26163604 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant Reiki (5 sessions, 30 min each night)
Number of subjects: 100
Study 26163604 — intervention group
Group type: COMPARATOR
Intervention: Usual medical and nursing care (Control)
Number of subjects: 100
Study 23665370 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise training (ET) for 16 weeks (walking, arm and leg ergometry, n = 32)
Number of subjects: 63
Study 23665370 — intervention group
Group type: COMPARATOR
Intervention: Attention control (CT) for 16 weeks (n = 31)
Number of subjects: 63
Study 21334033 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral beta-blockers
Number of subjects: 40
Study 21334033 — intervention group
Group type: COMPARATOR
Intervention: Intravenous beta-blockers
Number of subjects: 40
Study 19831159 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based aerobic and progressive resistance exercise intervention
Number of subjects: 38
Study 19831159 — intervention group
Group type: COMPARATOR
Intervention: No exercise (Control)
Number of subjects: 38
Study 17721096 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 therapy (subcutaneous IL-2, median of ten 5-day cycles)
Number of subjects: 131
Study 14994390 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac (300 or 1000 mg daily)
Number of subjects: 1433
Study 14994390 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (2400 mg daily)
Number of subjects: 1433
Study 14994390 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-DMARD treatment)
Number of subjects: 1433
Study 11773161 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 plus histamine (1.0 mg bid SC days 1 to 5, weeks 1 to 4)
Number of subjects: 305
Study 11773161 — intervention group
Group type: COMPARATOR
Intervention: IL-2 alone (9 MIU/m(2) bid SC on days 1 to 2 of weeks 1 and 3, and 2 MIU/m(2) bid SC on days 1 to 5 of weeks 2 and 4)
Number of subjects: 305
Study 11773161 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 plus histamine
Number of subjects: 305
Study 9872184 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraclavicular lymph node involvement (SCLN)
Number of subjects: 1370
Study 9872184 — intervention group
Group type: COMPARATOR
Intervention: Limited forms without SCLN
Number of subjects: 1370
Study 9872184 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited forms with SCLN
Number of subjects: 1370
Study 9872184 — intervention group
Group type: COMPARATOR
Intervention: Extensive forms without SCLN
Number of subjects: 1370
Study 9872184 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive forms with SCLN
Number of subjects: 1370
Study 9872184 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival rates
Number of subjects: 1370
Study 7648827 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous insulin (1.8U over 15 min)
Number of subjects: 10
Study 7648827 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous insulin (1.8U over 15 min, extended over 30 min)
Number of subjects: 10
Study 7648827 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous insulin (3.6U over 60 min)
Number of subjects: 10
Study 7648827 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementary insulin)
Number of subjects: 10
Study 2520792 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic catheter (SPC)
Number of subjects: 90
Study 2520792 — intervention group
Group type: COMPARATOR
Intervention: Transurethral catheter (TUC)
Number of subjects: 90
Study 1131130 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise (21% of max leg extension force for 1 min followed by 1-min rest) during bedrest periods.
Number of subjects: 7
Study 1131130 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic exercise (68% of max VO2) for 0.5 hours in the morning and afternoon during bedrest periods.
Number of subjects: 7
Study 1131130 — intervention group
Group type: COMPARATOR
Intervention: No exercise during the third bedrest period.
Number of subjects: 7
Study 1131130 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory control period (exercise on a bicycle ergometer at 50% of max VO2 for 1 h/d).
Number of subjects: 7
Study 30442551 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 15mg (oral)
Number of subjects: 30
Study 30442551 — intervention group
Group type: EXPERIMENTAL
Intervention: Auriculotherapy
Number of subjects: 30
Study 30442551 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet (oral) and sham auriculotherapy
Number of subjects: 30
Study 28991370 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 2 weeks (IXE Q2W)
Number of subjects: 3966
Study 28991370 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 4 weeks (IXE Q4W)
Number of subjects: 3966
Study 28991370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3966
Study 28991370 — intervention group
Group type: COMPARATOR
Intervention: Etanercept 50 mg biweekly
Number of subjects: 3966
Study 27471808 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal infiltration with articaine
Number of subjects: 30
Study 27471808 — intervention group
Group type: COMPARATOR
Intervention: Inferior alveolar nerve block with lignocaine
Number of subjects: 30
Study 24378475 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical hypothyroidism
Number of subjects: 1904
Study 24378475 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical hypothyroidism
Number of subjects: 1904
Study 24378475 — intervention group
Group type: COMPARATOR
Intervention: Normal thyroid function
Number of subjects: 1904
Study 22765978 — intervention group
Group type: EXPERIMENTAL
Intervention: CPOX4 variant boys
Number of subjects: 507
Study 22765978 — intervention group
Group type: COMPARATOR
Intervention: CPOX4 non-variant boys
Number of subjects: 507
Study 22765978 — intervention group
Group type: EXPERIMENTAL
Intervention: CPOX4 variant girls
Number of subjects: 507
Study 22765978 — intervention group
Group type: COMPARATOR
Intervention: CPOX4 non-variant girls
Number of subjects: 507
Study 20178033 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (selective serotonin reuptake inhibitor), duration: 12 weeks
Number of subjects: 2
Study 18066957 — intervention group
Group type: EXPERIMENTAL
Intervention: Less tight control
Number of subjects: 132
Study 18066957 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight control
Number of subjects: 132
Study 18066957 — intervention group
Group type: COMPARATOR
Intervention: Control group (less tight)
Number of subjects: 132
Study 18066957 — intervention group
Group type: COMPARATOR
Intervention: Control group (tight)
Number of subjects: 132
Study 15891594 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine infusion with 99mTc‐tetrofosmin
Number of subjects: 51
Study 15891594 — intervention group
Group type: COMPARATOR
Intervention: Resting state with 99mTc‐tetrofosmin
Number of subjects: 51
Study 11907350 — intervention group
Group type: EXPERIMENTAL
Intervention: Currently available IBD therapies and those used in clinical trials for ulcerative colitis.
Number of subjects: 0
Study 9830250 — intervention group
Group type: EXPERIMENTAL
Intervention: Low executive cognitive functioning (ECF)
Number of subjects: 249
Study 9830250 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult temperament
Number of subjects: 249
Study 9830250 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined influence of low ECF and difficult temperament
Number of subjects: 249
Study 9830250 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ECF
Number of subjects: 249
Study 9830250 — intervention group
Group type: EXPERIMENTAL
Intervention: ECF
Number of subjects: 249
Study 8006126 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial cycle (Goserelin 3.6 mg s.c. followed by hormone replacement therapy)
Number of subjects: 14